Researchers said the findings, published in the journal BMJ Open, may suggest a potential role for GLP-1 medications in the context of alcohol use disorder, although further research is needed
Additionally, patients should discuss comorbidities like pancreatitis history, recent surgery, or concomitant weight-loss medications
[3] On the more serious side, if someone takes too high a dose or has a specific sensitivity, it could cause confusion or tremors, or in rare cases, symptoms of serotonin overload like agitation and a rapid heart rate (especially if combined with certain antidepressants)
Safety of Cagrinlitide and CagriSema In the obesity trial, the proportions of participants who discontinued study treatment due to adverse events were 2-6Percentage, 7Percentage, and 3Percentage in the cagrilintide, liraglutide and placebo groups, respectively [9]
scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise in type 2 diabetes (T2D)
